• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Zydus Cadila receives final approval from USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

expresspharmaJuly 05, 2021

Tag: Zydus , Emtricitabine , Tenofovir , HIV

Zydus Cadila has received final approval from the USFDA to market Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg, a company statement said.

Zydus Cadila receives final approval from USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

The drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in one’s body so that the immune system can work better.

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Previous:Adroit Biomed launches Glutone MD made from purest Setria Glutathione

Next:Bharat Biotech announces data from phase-III Covaxin clinical trials

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Zydus Cadila receives final approval from USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Tenofovir Disoproxil Fumarate

Tenofovir Disoproxil Fumarate
Tenofovir

Tenofovir
Tenofovir disoproxil

Tenofovir disoproxil
Tenofovir alafenamide fumarate

Tenofovir alafenamide fumarate
Emtricitabine

Emtricitabine
Emtricitabine Impurity A

Emtricitabine Impurity A
Tenofovir Disoproxil Furmarate tablet 150mg, 200mg, 250mg, 300mg

Tenofovir Disoproxil Furmarate tablet 150mg, 200mg, 250mg, 300mg
Tenofovir Disoproxil Fumarate

Tenofovir Disoproxil Fumarate
Emtricitabine intermediates FCME

Emtricitabine intermediates FCME
Tenofovir impurity

Tenofovir impurity

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service